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S U M M A R Y
Objective: A shift in the age of hepatitis A virus (HAV) infection from early childhood to adulthood has
been observed in many developing countries. This epidemiological shift has been attributed to improved
socioeconomic status and sanitary conditions resulting in growing cohorts of susceptible young people
and hence an increased risk of HAV outbreaks. The aim of this study was to investigate the evolutionary
trend of anti-HAV seroprevalence in Lebanon in a cohort of Lebanese adults.
Methods: This was a cross-sectional study employing a convenience sample (voluntary blood donors)
along with secondary data analysis. Sera from 283 healthy blood donors were tested for anti-HAV IgG
antibodies. Moreover, we analyzed the national reports of HAV cases published by the Lebanese Ministry
of Public Health since 2001.
Results: Anti-HAV seropositivity increased steadily from 60% in the younger age group (19–29 years) to
91% in the older age group (50–59 years), leaving the younger group at higher risk of acquiring HAV. The
national data show that the number of acute hepatitis A infections is higher in the age groups 5–9 and
10–19 years.
Conclusion: Our seroprevalence data reveal that young adults are becoming more at risk of acquiring
HAV infection. Thus the introduction of hepatitis A vaccine is highly recommended.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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The hepatitis A virus (HAV) is a non-enveloped single-stranded
positive-sense RNA virion belonging to the family Picornaviridae,
genus Hepatovirus.1 Worldwide, tens of millions of hepatitis A
cases occur annually.2 HAV is transmitted mainly through the
fecal–oral route, either by direct contact with an infected person or
by the consumption of contaminated food, raw seafood, or
contaminated drinking water.3 Hepatitis A infection is mainly
asymptomatic among children aged <6 years and symptomatic
among older children and adults. Symptoms include fever, nausea,
anorexia, abdominal discomfort, and jaundice.4 It is well estab-
lished that an improvement in economic conditions and the
associated increased access to clean water and better sanitation
leads to a reduction in the endemicity of HAV infection in
developing countries, including countries of the Middle East and
North Africa (MENA) region.2* Corresponding author. Tel.: +961 1 350000x4698; fax: +961 1 744470.
E-mail address: sramia@aub.edu.lb (S. Ramia).
http://dx.doi.org/10.1016/j.ijid.2014.10.007
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).During the past three decades, two major observations have
been made. The ﬁrst is that there has been a gradual shift in the age
of infection from early childhood to adulthood in many of the
developing countries.5 This shift, referred to as epidemiological
shift, has been attributed mainly to improved socioeconomic
status and sanitary conditions3 resulting in growing cohorts of
susceptible young people and hence an increased risk of hepatitis A
outbreaks. Second, the clinical picture of hepatitis A disease
appears to be changing from asymptomatic or mild infection,
which is the case in early childhood infection, to symptomatic
infection with jaundice in adults.4
Studies on anti-HAV seroprevalence estimates clearly show that
middle-income countries in Asia, Latin America, Eastern Europe, and
the Middle East have an intermediate or low level of HAV endemicity
and consequently may suffer from an increasing burden of hepatitis
A infection.2 Recently, we reviewed the data available for the past
10 years on anti-HAV seroprevalence in countries of the MENA
region. Twelve out of 25 MENA countries have shown a clear shift in
HAV incidence with a decline among the younger age groups and an
increase among adults and older individuals.6 These results are in
accordance with those for other areas of the world.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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neighboring countries (Lebanon, Turkey, Jordan, and Iraq) and
their settlement in densely populated camps has increased the risk
of disease; the poor sanitation, unclean water supplies, and low-
quality housing in these camps are all likely to contribute to the
rapid spread of diseases, including hepatitis A.7 These changes
have increasingly compelled the reluctant public health authori-
ties in developing countries to introduce hepatitis A vaccination in
order to prevent and/or minimize the risk of HAV infection.
However, there is a general lack of updated data on the burden of
hepatitis A disease and its incidence and age-speciﬁc seropreva-
lence, and these data are required prior to the introduction of any
vaccination program in most developing countries.
To better understand the current evolutionary trend of HAV
seroprevalence in Lebanon as compared to countries of the MENA
region, we estimated the seroprevalence of anti-HAV antibodies in
a cohort of Lebanese adults and reviewed the cases of acute HAV
infection reported during the past decade by the Epidemiological
Surveillance Unit (ESU) of the Ministry of Public Health (MOPH).
2. Methods
This is a cross-sectional study employing a convenience sample
(voluntary blood donors) along with secondary data analysis. This
study was approved by the Institutional Review Board of the
American University of Beirut. The study was performed in
compliance with the relevant laws and institutional guidelines
and in accordance with the ethical standards laid down in the
Declaration of Helsinki.
Whole blood was collected from 283 healthy Lebanese blood
donors (aged 19–59 years) presenting at Hammoud Hospital, Saida
(South Lebanon) and the American University of Beirut Medical
Center (AUBMC) between October 2012 and March 2013. The
study participants were from the Beirut area and the southern part
of Lebanon. Serum samples were obtained and stored at 20 8C
until tested. Anti-HAV IgG antibodies were detected using a
commercially available ELISA kit (Architect HAVAb-IgG) as per the
manufacturer’s instructions. The Architect i 100 SR machine
(Abbott Laboratories, Germany) was used to analyze anti-HAV
levels. Moreover, we evaluated the reports of the ESU on HAV
infections by age at the national level in an attempt to assess the
changing epidemiology of HAV over time.
3. Results
Table 1 summarizes the demographic characteristics of the
healthy blood donors enrolled (n = 283). The majority of study
participants were male. Forty-eight percent of these participants
were aged 19–29 years and 36% were holders of a universityTable 1
Demographic characteristics of the study participants
Number (N = 283) Percentage
Gender
Male 221 78.0
Female 62 21.9
Age, years
19–29 137 48.4
30–39 75 26.5
40–49 48 16.9
50–59 23 8
Education
Illiterate 9 3.2
Primary school 30 10.5
Secondary school 80 28.1
High school 63 22.2
University level 101 35.7degree. Moreover, the majority of study participants lived in non-
crowded settings. Our study did not include children and young
adults aged less than 19 years. Data on the participants’
vaccination status were not collected.
The overall prevalence of anti-HAV among our study partici-
pants was 72%. The anti-HAV seropositivity rate within age groups
19–29, 30–39, 40–49, and 50–59 years increased gradually or
steadily from the lower age group (60%, age 19–29 years or young
adults) to the older age group (91%, age 50–59 years). Accordingly,
40% of our tested young adults aged 19–29 years were anti-HAV-
negative as compared to 23%, 6%, and 9% for age groups 30–39, 40–
49, and 50–59 years, respectively (Figure 1).
The ESU at the MOPH collects data on HAV cases from different
regions of Lebanon. Table 2 shows the number of HAV infections
per year for the following age groups: 0–4, 5–9, 10–19, 20–39, 40–
59 and 60 years. The total number of acute cases reported by the
ESU during the years 2001–2014 was 7501 cases.8 These reports
were used to assess the epidemiology of hepatitis A by age at the
national level. The largest number of reported hepatitis A cases was
found to be clustered among children and adolescents aged 5–9
and 10–19 years during 2001–2014 (Table 2). The national data
presented does not show a speciﬁc trend in which HAV infections
are clustered in one speciﬁc area. The highest number of HAV cases
reported during 2007–2014 originated from the Bequaa area,
whereas the southern part of Lebanon as well as Beirut were
characterized by lower numbers of HAV cases (data not shown).
4. Discussion
The detection of anti-HAV antibodies by age is an important
measure of age-speciﬁc incidence rates of HAV infection.9 This is
critical to assess the evolutionary shift of the risk of HAV
acquisition. Overall, our data show that anti-HAV seropositivity
is increasing with age, with 94% and 91% of our study participants
in the 40–49 and 50–59 years age groups, respectively, being
positive for anti-HAV antibodies. Previous data from Lebanon have
indicated a gradual increase in anti-HAV seroprevalence with age,
with 11%, 28%, 57%, and 70% of subjects aged 1–5, 6–10, 11–15, and
16–20 years, respectively, being positive for anti-HAV.10 While we
did not test for anti-HAV antibody levels among children and
young adolescents, this is the ﬁrst report on anti-HAV seropreva-
lence rates among adults of different age groups in Lebanon, albeit
with a small sample size. Our seroprevalence data reveal that
younger Lebanese adults are more at risk of acquiring HAV0
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Figure 1. The percentage of anti-HAV antibodies in sera of the study participants.
Sera from 283 healthy Lebanese blood donors were tested for anti-HAV antibodies
using ELISA. The percentage of anti-HAV positive sera (y-axis) was plotted against
the following age groups (x-axis): 19–29, 30–39, 40–49, and 50–59 years.
Table 2
Number of hepatitis A cases by age in Lebanon, 2001–2014
Year Age, years Total
0–4 5–9 10–19 20–39 40–59 60+
2001 43 119 82 25 1 4 274
2002 42 96 105 51 3 4 301
2003 79 214 181 81 4 5 564
2004 51 112 127 74 8 2 374
2005 33 54 62 31 3 5 188
2006 24 83 115 60 7 2 291
2007 65 151 209 98 8 3 534
2008 85 190 219 120 9 2 625
2009 66 156 293 168 13 3 699
2010 33 85 101 88 8 3 318
2011 48 130 172 83 7 1 441
2012 125 188 266 144 17 4 744
2013 161 360 592 357 35 6 1511
2014 60 146 261 157 10 3 637
Total 915 2084 2785 1537 133 47 7501
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increased susceptibility to HAV infection at a younger age, which
will consequently increase the likelihood of HAV outbreaks among
young Lebanese adults.
The national data also reﬂect the change in epidemiology of
HAV infection over time; the younger age groups, speciﬁcally age
0–9 years, are becoming more susceptible to HAV infection over
time in Lebanon as compared to adults aged 10–39 years. This
again suggests an epidemiological shift in age-speciﬁc HAV
infection. This shift occurred in most developed countries several
decades ago and most noticeably in countries with increasing
economic growth such as Spain and Korea.11 Furthermore, a
number of countries in the MENA region such as Saudi Arabia,12
Kuwait,13 United Arab Emirates,14 and others,11 have reported
similar trends during the last 5 years.
According to a systematic review on the global prevalence of
HAV infection published by the World Health Organization (WHO,
2009),11 MENA countries have intermediate levels of anti-HAV
seroprevalence. Although differences occur among MENA coun-
tries and within the countries themselves, it is estimated that more
than 80% of the adult population and more than 50% of children in
the region are immune against HAV. Seroprevalence levels of anti-
HAV among adults have remained consistently high in most
countries in the MENA region. However, these levels have
exhibited a decline among children in Saudi Arabia, Egypt, Jordan,
Iran, and Turkey.11 It is clear that the trends reported by the WHO
report up until 2009 are still holding up in Iran,15–21 Iraq,22 Saudi
Arabia,23 and Turkey;24–28 i.e., lower age groups and speciﬁcally
children and young adults have lower anti-HAV seroprevalence.
Overall, our results reveal the age-related HAV epidemiological
shift in Lebanon with a relatively low anti-HAV seroprevalence
detected in young adults. This results in an increased susceptibility
of younger age groups and consequently draws attention to the
importance of vaccination against HAV. Our data are similar to
those reported in other MENA countries.
Despite the effectiveness of the currently available HAV
vaccines and their ability to reduce hepatitis A, recommendations
on the use of the vaccine vary considerably among different
countries. In a recent position paper, the WHO (2012)9 recom-
mended that vaccination against hepatitis A should be integrated
into the national immunization schedule for children aged 1 year
based on the incidence of acute hepatitis and depending on the
change in the endemicity level of the respective country and on the
cost-effectiveness of vaccination. Hence, three strategies could be
followed: (1) In countries shifting from high to intermediate HAV
where a large part of the adult population is susceptible to HAV
infection, vaccination is recommended; (2) In countries with lowendemicity, vaccination of high-risk groups should be considered;
this targeted vaccination should include men who have sex with
men, injecting drug users, and travelers to high or intermediate
endemic countries, in addition to patients with chronic liver
disease at an increased risk of fulminant hepatitis A; (3) Early
during an HAV outbreak, a single dose vaccine should be used; this
was previously found to be successful when different age cohorts
were covered.
To our knowledge, immunization against HAV is incorporated
in the routine childhood immunization programs of Bahrain,
Cyprus, Iraq, Israel, Saudi Arabia, and Qatar.29 Hepatitis A vaccine is
offered to children in two doses during the ﬁrst two years of life, as
well as to high-risk groups (the latter is applied speciﬁcally in
Cyprus, Iraq, and Israel). These two doses are currently recom-
mended to ensure long-term protection following vaccination
during the ﬁrst two years of life.9
The poor sanitation, unclean water supplies, and low-quality
housing in densely populated refugee camps in countries
neighboring Syria have all contributed to the rapid spread of
disease in these camps.7 Such conditions are expected to inﬂuence
the epidemiology of several infectious diseases including hepatitis
A. HAV outbreaks have been reported in Syrian refugee camps in
Iraq and Jordan. The incidence of hepatitis A among the refugee
population may result in an overall increase in hepatitis A
infections within the host country given the high mobility and
interaction with the host community. Consequently, Lebanon and
other MENA countries urgently need to introduce HAV vaccines,
not only as an emergency response measure but also as long-term
protection for the entire population. The hepatitis A vaccine can be
administered with all other vaccines included in the Expanded
Programme on Immunization.30
There are several limitations to this study, including the small
sample size and the lack of representation from different parts of
Lebanon for comparative analysis of national seroprevalence data.
Importantly, we did not have data on anti-HAV seroprevalence for
high-risk groups or data for the younger age groups. Similarly, we
did not know the vaccination status of the participants, who may
possibly have been vaccinated against HAV despite the lack of a
standardized vaccine policy. In fact, we have recently reported the
lack of anti-HAV seroprevalence data representative of the entire
population in many countries of the MENA region, reporting on the
former during the past decade.7 Nevertheless, we believe that this
study provides preliminary data on seroprevalence trends among
adults in Lebanon. Further studies are needed to test the anti-HAV
seroprevalence at the country level (i.e. population-based sero-
prevalence studies) across all age groups and also of the different
subpopulations with different prevalence levels (high or low) of
HAV infection, to determine the current endemicity of HAV.
Lebanon does not have a national policy to immunize against
hepatitis A. Our data conﬁrm the epidemiological shift in the
incidence of hepatitis A infection despite the limitation of testing a
relatively small sample and the lack of data on high-risk groups.
The introduction of hepatitis A vaccine to reduce the risk of
morbidity and mortality among susceptible children and adoles-
cents should be considered seriously. We recommend the
intensiﬁcation of the surveillance system to estimate the national
burden of hepatitis A on a continuous basis.
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